NetForum uses cookies to ensure that we give you the best experience on our website. If you continue to use the site, we'll assume that you are happy to receive these cookies on the NetForum website. Read about our cookies.
NetForum Community
Learn. Share. Optimize.
Log in | Sign up now | Submit content | Contact

Attention valued NetForum members:

Due to evolving technology needs and global privacy regulations, we have made the hard decision to suspend the NetForum User Community platform on Friday, November 29, 2019.

After this date, the current NetForum can no longer be reached. Please click here for more information about this decision, what happens next and how to stay in touch with us about the future of the community.

Go to similar content

Effect of sarpogrelate on characteristics of coronary artery disease in patients with type 2 diabetes

Philips CT Clinical Science Philips Healthcare • USA

Lee DH, Chun EJ, Hur JH, Min SH, Lee JE, Oh TJ, Kim KM, Jang HC, Han SJ, Kang DK, Kim HJ, Lim S.


* This article originally appeared in the February 2017 issue of Atherosclerosis.

Background and Aims

Sarpogrelate, a 5-hydroxytryptamine type 2A antagonist, is a potential antiplatelet agent. We performed a randomized study to evaluate the effect of sarpogrelate on vascular health in Korean patients with diabetes.



Forty diabetic patients aged 58.6 ± 6.8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for six months. The primary endpoint of this study was the change in coronary artery disease including the calcium score (CACS), maximal stenosis, and plaque volume (calcified vs. non-calcified). The secondary endpoints were changes in biochemical parameters related to glucose and lipid metabolism, and in subclinical atherosclerosis assessed by ankle-brachial index and pulse wave velocity.



After six-month treatment, there was no significant difference in the changes in CACS, coronary stenosis, ankle-brachial index, and pulse wave velocity, between groups. The total plaque volume decreased from 82.4 ± 14.5 mm³ to 74.6 ± 14.4 mm³ in the SPG + ASA group, but increased from 64.9 ± 16.0 mm³ to 68.6 ± 16.3 mm³ in the ASA group (p < 0.05), mainly driven by changes in the non-calcified component (SPG + ASA group 15.6 ± 4.6 mm³ to 11.2 ± 3.7 mm³ vs. ASA group 21.2 ± 6.2 mm³ to 22.8 ± 6.6 mm³, p < 0.01). Serum C-reactive protein levels and homeostasis model assessment of insulin resistance tended to decrease in the SPG + ASA group, but they were not altered in the ASA group.



The present study demonstrated that sarpogrelate treatment may decrease coronary artery plaque volume, particularly the non-calcified portion, in patients with diabetes.

For more information about this publication, check out the PubMed listing for this article.

This content has been made possible by NetForum Community.
Share this on: Share your link in twitter Share your link in facebook Share your link on LinkedIn Print Rate this article: Log in to vote

Nov 20, 2017

Rate this:
Log in to vote

atherosclerosis, calcium score, Cardiac, Cardiac Viewer, Comprehensive Cardiac Analysis, coronary angiography, coronary arteries, coronary artery disease, diabetes, Extended Brilliance Workspace 4.5, plaque, stenosis, Vascular

Clinical News
Best Practices
Case Studies
Publications and Abstracts
White Papers
Web seminars and Presentations
Application Tips and FAQ
Try an Application
Business News
Case Studies
White Papers
Web Seminars and Presentations
Utilization Services
Contributing Professionals
Contributing Institutions
Become a Contributor